Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2007
Business Overview: Cardinal Health is a leading provider of products and services that improve the safety and productivity of healthcare. The company operates through four primary reportable segments: Healthcare Supply Chain Services (Pharmaceutical and Medical), Clinical Technologies and Services, and Medical Products Manufacturing. The company distributes approximately one-third of all pharmaceuticals prescribed in the United States.
Key Financial Metrics
| Metric | Fiscal 2007 | Fiscal 2006 |
|---|---|---|
| Revenue | $86,852.0 million | $79,664.2 million |
| Gross Margin | $5,245.3 million | $4,814.0 million |
| Operating Earnings | $1,373.7 million | $1,844.9 million |
| Net Earnings | $1,931.1 million | $1,000.1 million |
| Diluted EPS | $4.77 | $2.33 |
| Cash from Operating Activities (Continuing) | $1,003.0 million | $1,850.2 million |
| Total Assets | $23,153.8 million | $23,433.3 million |
| Long-term Obligations | $3,457.3 million | $2,588.6 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 9% to $86.9 billion, driven by growth in all segments, particularly the Healthcare Supply Chain Services - Pharmaceutical segment ($6.5 billion increase), largely due to bulk customer volume and pharmaceutical price appreciation.
- Operating Earnings Decline: Operating earnings decreased 26% to $1.4 billion. This decline was primarily due to $772 million in special items, including $655 million in litigation settlement reserves and $85 million in in-process research and development (IPR&D) expenses related to the Viasys acquisition.
- Net Earnings Surge: Net earnings increased 93% to $1.9 billion. This significant increase was driven by a $1.1 billion after-tax gain from the sale of the Pharmaceutical Technologies and Services (PTS) Business, which was classified as discontinued operations.
- Segment Performance: Segment profit increased in all four reportable segments. The Healthcare Supply Chain Services - Pharmaceutical segment profit grew 14%, while Clinical Technologies and Services and Medical Products Manufacturing both grew 20%.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
- Strategic Shifts: The company completed the sale of the PTS Business for approximately $3.2 billion in cash, using the proceeds to repurchase shares. It also acquired Viasys Healthcare Inc. ($1.5 billion) to expand its medical products portfolio.
- Shareholder Returns: The company repurchased approximately $3.8 billion of common shares during fiscal 2007 and increased the quarterly dividend by 33% to $0.12 per share in the fourth quarter.
- Future Outlook: Management expects continued competitive pricing pressures but anticipates mitigation through sales growth of higher-margin manufactured products and cost controls. The company is implementing a new accounting software system throughout fiscal 2008 and 2009.
Risks and Contingencies
- Customer Concentration: The five largest customers accounted for approximately 50% of revenue. CVS Corporation (21%) and Walgreen Co. (19%) are the top two customers.
- Regulatory and Legal: The company faces significant litigation risks, including settlements related to federal securities litigation ($600 million) and ERISA litigation ($40 million). It is also subject to ongoing investigations regarding Medicaid rebates for repackaged pharmaceuticals.
- Pharmaceutical Pricing: The business model relies on pharmaceutical price appreciation and manufacturer rebates. A slowdown in price appreciation or acceleration in generic price deflation could adversely affect results.
- Product Recall: The company initiated a voluntary corrective action for the Alaris SE pump due to a "key bounce" risk, resulting in a $13.5 million charge in the prior year and ongoing compliance costs.
Key Facts for Investor Verification
- Discontinued Operations Impact: Verify the sustainability of earnings by excluding the $1.1 billion one-time gain from the sale of the PTS Business, which significantly inflated net earnings for the period.
- Special Items: Review the $772 million in special items, specifically the $655 million litigation reserve, to understand the true operating performance of continuing operations.
- Customer Concentration: Assess the risk associated with the top five customers representing 50% of total revenue.
- Acquisition Integration: Monitor the integration of the Viasys acquisition and the associated $85 million IPR&D charge to evaluate future growth potential in the Medical Products Manufacturing segment.
- Share Repurchases: Note that the company utilized proceeds from the PTS sale to fund a significant portion of its $3.8 billion share repurchase program.